Latest Superannuation News

Prophecy International has appointed Jonathan Drake as CEO effective July 2026, aiming to strengthen leadership after a period of interim management and strategic recalibration.

Platina Resources has appointed Dr Paul Polito as Managing Director and CEO, bringing over 30 years of exploration expertise to lead its Western Australian gold projects. His remuneration is heavily tied to operational milestones and share price performance.

Talisman Mining has appointed Todd Ross as CEO, initiating a leadership transition as the company advances drilling programs in NSW. Ross's extensive mining and finance background aims to unlock value across Talisman's exploration portfolio.

Equity Trustees Superannuation Limited (ETSL) will contest ASIC's Federal Court civil proceedings related to the First Guardian Master Fund, where member losses total around $70 million. The trustee insists it acted within its fiduciary duties amid ongoing liquidation efforts.

Ausgold Limited has promoted Ben Stockdale from CFO to CEO and appointed Reece Olney as GM Operations, reinforcing its leadership as the Katanning Gold Project approaches a final investment decision.

Commonwealth Bank of Australia reported a steady cash profit of around $2.7 billion in 3Q26, balancing disciplined lending growth and cautious provisioning amid geopolitical and economic uncertainties.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

Besra Gold appoints Dr Raymond Shaw as CEO, leveraging his four decades of experience to steer the Bau Gold project through ongoing operational and strategic hurdles.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.

The GPT Group delivered strong operational results in Q1 2026 with near-record occupancy across retail, office, and logistics assets, alongside solid retail sales and leasing activity. The group’s $610 million oversubscribed equity raise in its Wholesale Shopping Centre Fund underpins growth plans, while FY 2026 earnings guidance is reiterated.